Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

1462006

USP

Nicotinamide

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Nicotinamide, Niacinamide, Nicotinic acid amide, Pyridine-3-carboxylic acid amide, Vitamin B3, Vitamin PP

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C6H6N2O
Número de CAS:
98-92-0
Peso molecular:
122.12
Beilstein/REAXYS Number:
383619
MDL number:
MFCD00006395
UNSPSC Code:
41116107
PubChem Substance ID:
329750553
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nicotinamide

manufacturer/tradename

USP

mp

128-131 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Niacinamide USP reference standard for use in specified quality tests and assays.

Also used to prepare standard, Niacin standard solution, standard niacinamide stock solution, and sample solution for assay, performance, and strength analysis according to the given below monographs and general chapters of United States Pharmacopeia (USP):
  • Niacinamide
  • Niacinamide Tablets
  • Niacinamide Injection
  • 〈441〉 Niacin or Niacinamide Assay

Biochem/physiol Actions

Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

N0600000

Nicotinamide, European Pharmacopoeia (EP) Reference Standard

E2400000

Ethylnicotinamide, European Pharmacopoeia (EP) Reference Standard

BP460

Nicotinamide, British Pharmacopoeia (BP) Reference Standard

BP1104

N-(2-Hydroxyethyl)isonicotinamide nitric ester, British Pharmacopoeia (BP) Reference Standard

PHR2089

Nicotinamide Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2090

Nicotinamide Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2088

Nicotinamide Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2087

Nicotinamide Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H319

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

302.0 °F - closed cup

flash_point_c

150 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Niacinamide Injection
United States Pharmacopeia, 46(5) (2023)
Mitchell E Horwitz et al.
The Journal of clinical investigation, 124(7), 3121-3128 (2014-06-10)
Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis
Geert O Janssens et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1112-1119 (2014-01-16)
Retrospective studies indicate that larger tumour volume is a strong prognostic indicator for poor tumour control after (chemo)radiotherapy for laryngeal cancer. The impact of tumour volume on the outcome of patients treated within a prospective study comparing accelerated radiotherapy (AR)±carbogen
Marcia S Brose et al.
Lancet (London, England), 384(9940), 319-328 (2014-04-29)
Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment
Fabrizio Montecucco et al.
Current drug targets, 14(6), 637-643 (2013-03-28)
Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico